NMDBF - NMDBF STOCK NEWS

NeonMind Biosciences (OTCQB:NMDBF) announced plans to launch its first specialty clinic in Canada by early 2022. These NeonMind-branded clinics will focus on providing innovative interventional psychiatry treatments, targeting underserved populations. The initiative follows the establishment of a new Specialty Clinics Advisory Board to oversee operations. With increasing demand for mental health solutions, particularly during the COVID-19 pandemic, NeonMind aims to position itself as a leader in the evolving field of interventional psychiatry.

NeonMind Biosciences Inc. has appointed Dr. Gustavo Vazquez, a renowned expert in mood disorders and ketamine treatments, to its Specialty Clinics Advisory Board. This strategic addition aims to enhance the company's development of a specialty clinics network that offers effective treatments for mood disorders. Dr. Vazquez brings extensive experience from his role at Queen's University and his leadership at a successful Ketamine Clinic in Canada. His expertise is expected to strengthen NeonMind’s initiatives in providing innovative mental health solutions.

NeonMind Biosciences Inc. has appointed Dr. Roumen Milev, a renowned expert in interventional psychiatry, to its Specialty Clinics Advisory Board. This strategic move aims to enhance the company's network of specialty clinics focused on effective treatments for mental health disorders, utilizing ketamine and neurostimulation modalities. Dr. Milev’s extensive experience includes treating over 1,000 patients and leading various mental health initiatives. NeonMind seeks to integrate innovative therapies into traditional psychotherapy to improve patient access and outcomes in mental health care.

NeonMind Biosciences Inc. (NMDBF) announced the successful sale of its consumer division assets for approximately C$1.1 million, focusing its efforts on psychedelic drug development. The divestiture aligns with the company’s strategy to advance NEO-001, a synthetic psilocybin drug targeting obesity. With positive pre-clinical data and regulatory meetings planned for Q4 2021, NeonMind aims to establish itself in interventional psychiatry. The company is also developing specialty mental health clinics to integrate psychedelics into treatments.

NeonMind Biosciences Inc. (CSE:NEON, OTCQB:NMDBF) is set to present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Robert Tessarolo, the President and CEO, will join the virtual event starting September 13 at 7:00 a.m. ET. NeonMind focuses on therapeutic uses of psilocybin for treating obesity and operates in three divisions: pharmaceuticals, medical services, and consumer products. Their lead drug candidates, NEO-001 and NEO-002, target obesity through psilocybin.

NeonMind Biosciences Inc. (OTCQB: NMDBF) has announced that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC). This eligibility enhances the accessibility of NeonMind's shares to a larger pool of investors, accelerating trade execution and increasing liquidity. The company's focus is on developing psilocybin-based treatments for obesity and wellness. NeonMind operates three divisions: pharmaceutical, medical services, and consumer products, with ongoing preclinical research on two drug candidates targeting obesity.

NeonMind Biosciences Inc. (CSE:NEON, OTCQB:NMDBF) announced approval from Health Canada for its 'Mindful Blend' functional mushroom product, which supports cognitive function and immune health. This product, made from 100% plant-based extracts, does not contain psychoactive substances. The approval enables NeonMind to market its mushroom ingredients, expanding its consumer products division amid a booming medicinal mushroom market projected to reach US$78.7 billion by 2025. The company also focuses on developing psilocybin-based treatments for obesity.

NeonMind Biosciences announced a strategic reorganization aimed at enhancing the execution of its integrated drug development plan for NEO-001, a psilocybin treatment targeting obesity. Key changes include the establishment of an R&D Advisory Board chaired by Philippe Martin, and an expanded regulatory team to support upcoming clinical trials. The company aims to prepare NEO-001 for a phase 1/2 study in obese patients while collaborating with regulatory authorities like the FDA and Health Canada. This reorganization represents a focused effort to streamline operations and enhance the regulatory pathway for its lead drug candidate.

NeonMind Biosciences Inc. (OTCQB:NMDBF) announced the appointment of Dr. Sagar Parikh to its Specialty Clinics Advisory Board, enhancing its leadership in the psychedelic treatment sector. Dr. Parikh, a distinguished psychiatrist with extensive experience in treating mood disorders, will guide the development of specialized clinic services. NeonMind focuses on psilocybin for treating obesity and mental health conditions, operating three divisions: pharmaceuticals, medical services, and consumer products. The company aims to offer tailored therapeutic solutions through its upcoming clinics.